Abstract Number: PB0476
Meeting: ISTH 2020 Congress
Background: Thrombomodulin is a membrane glycoprotein present on the surface of endothelial cells, which is often increased in response to diffuse endothelial damage.
Aims: To investigate thrombomodulin levels in women with breast cancer treated with doxorubicin (DOXO) and the association of this glycoprotein with molecular subtypes of breast cancer.
Methods: Our study included 80 breast cancer patients under treatment with DOXO attended at the Hospital Alberto Cavalcanti (FHEMIG). The study was approved by the Ethics Committee of the Federal University of Minas Gerais and FHEMIG, according to Declaration of Helsinki. All participating previously signed the informed consent form. Thrombomodulin levels in serum samples taken before (T0) and after the last cycle (T1) of chemotherapy were measured by Multiplex immunoassay. Patients were grouped according to molecular classification: luminal, HER2 positive (HER2+) and triple negative. A statistical analysis was performed in SPSS v.17.0 software.
Results: In all patients, the median thrombomodulin was 3.81 ng/mL (IQR 1.98) at T0 and 4.80 ng/mL (IQR 2.86) at T1 (p>0.05). The most frequent molecular classification was HER2+, n=33 (41.8%). At T0, median levels of thrombomodulin was 4.08 ng/mL (IQR 3.59) for luminal, 3.68 ng/mL (IQR 1.72) for HER2+ and 3.65 ng/mL (IQR 2.13) for triple negative. At T1, median levels of thrombomodulin was 4.93 ng/mL (IQR 3.31) for luminal, 4.45 ng/mL (IQR 2.52) for HER2+ and 4.97 ng/mL (IQR 1.92) for triple negative. There was no difference between the two times and the subtypes of breast cancer for thrombomodulin levels (p> 0.05).
Conclusions: The assessment of thrombomodulin cannot contribute to the evaluation of endothelial injury post-DOXO treatment in women with breast cancer and is not associated with the molecular subtype of tumor.
Acknowledgments: CNPq and FAPEMIG.
To cite this abstract in AMA style:Teodoro Alves Vieira M, Simões R, Silva LM, Oliveira HH, Souza ID, Carvalho MDG, Dusse LM, Sabino ADP, Pestana RM, Borges KB. Evaluation of Thrombomodulin Levels in Women with Breast Cancer Undergoing Doxorubicin Treatment [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/evaluation-of-thrombomodulin-levels-in-women-with-breast-cancer-undergoing-doxorubicin-treatment/. Accessed September 21, 2023.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/evaluation-of-thrombomodulin-levels-in-women-with-breast-cancer-undergoing-doxorubicin-treatment/